C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom
On Feb. 24, 2024, C2N Diagnostics (C2N) announced the medical device registration from the United Kingdom’s Medicines and…
On Feb. 24, 2024, C2N Diagnostics (C2N) announced the medical device registration from the United Kingdom’s Medicines and…
On Feb. 23, 2024, the California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative…
On Nov. 22, 2023, the U.S. Food and Drug Administration (FDA) issued the final guidance COVID-19: Developing Drugs…
On Aug. 31, 2023, study results published in JAMA found that psilocybin treatment was associated with a clinically…
On Jul. 27, 2023, the California Institute for Regenerative Medicine (CIRM) awarded $50.1 million to fund clinical-stage research…
On May 2, 2023, the U.S. Food and Drug Administration (FDA) announced that it was taking additional steps…
On Apr. 11, 2023, a National Institutes of Health (NIH) clinical trial was stopped early because a daily…
On Feb. 9, 2023, the National Institutes of Health (NIH) announced that a new large-scale genetic analysis found…
On Dec. 5, 2022, the Fred Hutchinson Cancer Center announced that according to a new meta-analysis women were…
On Nov. 15, 2022, Moderna reported findings from a Phase II/III clinical trial where bivalent Omicron-targeting booster candidates,…
On Sept. 13, 2022, the National Institutes of Health announced it will invest $130 million over four years,…
On Mar. 7, 2022, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2…
On Nov. 12, 2021, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2…
On Nov. 11, 2021, the University of Oxford began recruiting for a Phase I trial to test an…
On Oct. 6, 2021, Vaxart announced that it had begun recruiting subjects for its Phase II COVID-19 oral…
On Oct. 6, 2021, Lumen Bioscience announced new development funding from the US Army for its Covid-19 monoclonal…
On Sept. 23, 2021, Novavax with its partner, Serum Institute of India, announced a regulatory submission to the…
On Sept. 23, 2021, Novavax announced publication of complete results from a pivotal Phase 3 clinical trial of…
On Sept. 22, 2021, Inovio Pharmaceuticals announced that it had received authorization from COFEPRIS (Comisión Federal para la…
On Sept. 15, 2021, the National Institutes of Health (NIH) awarded nearly $470 million to build a national…
On Sept. 8, 2021, AIM ImmunoTech announced that is had submitted a Pre-Investigational New Drug application (Pre-IND) to…
On Sept. 8, 2021, Bio-Techne and Carterra announced a clinical research collaboration studying COVID-19 variants. To assess immune…
On Aug. 11, 2021, the National Institutes of Health (NIH) announced that one dose of a new monoclonal…
On Aug. 11, 2021, the World Health Organization (WHO) announced the next phase in its Solidarity trial that…
On Aug. 4, 2021, Inovio Pharma announced that the company had dosed the first Phase 2 trial subject…
On Aug. 3, 2021, CytoDyn announced that Brazil’s regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved…
On Jul. 29, 2021, the National Institutes of Health (NIH) announced it had launched a new online research…
On Jul. 28, 2021, GlaxoSmithKline and Vir Biotechnology announced they had signed a Joint Procurement Agreement with the…
On Jul. 26, 2021, Trevena announced that the first COVID-19 patient had been enrolled in the NIH-funded ACTIV-4…
On Jun. 29, 2021, Rigel Pharma announced that fostamatinib, the Company’s novel oral spleen tyrosine kinase (SYK) inhibitor,…